Cabazitaxel is primarily used in the treatment of metastatic prostate cancer that has progressed despite prior chemotherapy, particularly after the failure of docetaxel treatment. It works by inhibiting cell division, thereby slowing the growth and spread of cancer cells. Administered intravenously, it is often combined with prednisone to enhance its efficacy and manage side effects. Its application is critical for patients who have limited treatment options, offering a therapeutic alternative to improve survival rates and quality of life.